What Researchers Did
Researchers conducted a descriptive registry study using an international database to identify emerging indications for hyperbaric oxygen treatment.
What They Found
Out of 9726 patient entries, 378 (3.89%) were treated for 45 emerging indications, with post-COVID-19 condition (39.4%), ulcerative colitis (12.4%), and Crohn disease (10.6%) comprising 62.4% (n=236) of these cases. Patients with post-COVID-19 condition reported significant improvement in Neurobehavioral Symptom Inventory scores (30.6 pretreatment to 14.4 posttreatment; P<.001), and Crohn disease patients showed improved quality of life and 13% (5 patients) reported fistula closure. For ulcerative colitis, 50% (10/20) of patients with complete data achieved clinical remission.
What This Means for Canadian Patients
Canadian patients with conditions like post-COVID-19 symptoms, ulcerative colitis, or Crohn disease might eventually benefit from hyperbaric oxygen therapy as an emerging treatment option. While promising, these findings suggest potential new avenues for care, but further clinical trials are needed to establish efficacy and guidelines for widespread use.
Canadian Relevance
This study has no direct Canadian connection as it was conducted using an international registry without specific Canadian participation mentioned.
Study Limitations
As a descriptive registry study, this research cannot establish causality or definitive treatment efficacy due to the absence of control groups and potential for selection bias.